tetano
Editor, Senior Moderator
J Gen Intern Med
. 2021 Jan 22.
doi: 10.1007/s11606-020-06397-7. Online ahead of print.
Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians
Jessica R Cataldi[SUP] 1 2 [/SUP], Laura P Hurley[SUP] 3 4 [/SUP], Megan C Lindley[SUP] 5 [/SUP], Sean T O'Leary[SUP] 3 6 [/SUP], Carol Gorman[SUP] 3 [/SUP], Michaela Brtnikova[SUP] 3 6 [/SUP], Brenda L Beaty[SUP] 3 [/SUP], Lori A Crane[SUP] 3 7 [/SUP], David K Shay[SUP] 5 [/SUP], Allison Kempe[SUP] 3 6 [/SUP]
Affiliations
Abstract
Background: Several different types of influenza vaccine are licensed for use in adults in the USA including high-dose inactivated influenza vaccine (HD-IIV) and live attenuated influenza vaccine (LAIV). HD-IIV is licensed for use in adults ≥ 65 years, and recommendations for use of LAIV have changed several times in recent years.
Objective: We sought to examine family physicians' (FPs) and general internal medicine physicians' (GIMs) perceptions, knowledge, and practices for use of HD-IIV and LAIV during the 2016-2017 and 2018-2019 influenza seasons.
Design: E-mail and mail surveys conducted February-March 2017, January-February 2019.
Participants: Nationally representative samples of FPs and GIMs.
Main measures: Surveys assessed HD-IIV practices (2017), knowledge and perceptions (2019), and LAIV knowledge and practices (2017, 2019).
Key results: Response rates were 67% (620/930) in 2017 and 69% (642/926) in 2019. Many physicians believed HD-IIV is more effective than standard dose IIV in patients ≥ 65 years (76%) and reported their patients ≥ 65 years believe they need HD-IIV (67%). Most respondents incorrectly thought ACIP preferentially recommends HD-IIV for adults ≥ 65 years (88%); 65% "almost always/always" recommended HD-IIV for adults ≥ 65 years. Some physicians incorrectly thought ACIP preferentially recommends HD-IIV for adults < 65 years with cardiopulmonary disease (38%) or immunosuppression (48%); some respondents recommended HD-IIV for these groups (25% and 28% respectively). In 2017, 88% of respondents knew that ACIP recommended against using LAIV during the 2016-2017 influenza season, and 4% recommended LAIV to patients. In 2019, 63% knew that ACIP recommended that LAIV could be used during the 2018-2019 influenza season, and 8% recommended LAIV.
Conclusions: Many physicians incorrectly thought ACIP had preferential recommendations for HD-IIV. Physicians should be encouraged to use any available age-appropriate influenza vaccine to optimize influenza vaccination particularly among older adults and patients with chronic conditions who are more vulnerable to severe influenza disease.
Keywords: immunization; influenza; influenza vaccine; vaccination.
. 2021 Jan 22.
doi: 10.1007/s11606-020-06397-7. Online ahead of print.
Use of High-Dose Influenza and Live Attenuated Influenza Vaccines by US Primary Care Physicians
Jessica R Cataldi[SUP] 1 2 [/SUP], Laura P Hurley[SUP] 3 4 [/SUP], Megan C Lindley[SUP] 5 [/SUP], Sean T O'Leary[SUP] 3 6 [/SUP], Carol Gorman[SUP] 3 [/SUP], Michaela Brtnikova[SUP] 3 6 [/SUP], Brenda L Beaty[SUP] 3 [/SUP], Lori A Crane[SUP] 3 7 [/SUP], David K Shay[SUP] 5 [/SUP], Allison Kempe[SUP] 3 6 [/SUP]
Affiliations
- PMID: 33483822
- DOI: 10.1007/s11606-020-06397-7
Abstract
Background: Several different types of influenza vaccine are licensed for use in adults in the USA including high-dose inactivated influenza vaccine (HD-IIV) and live attenuated influenza vaccine (LAIV). HD-IIV is licensed for use in adults ≥ 65 years, and recommendations for use of LAIV have changed several times in recent years.
Objective: We sought to examine family physicians' (FPs) and general internal medicine physicians' (GIMs) perceptions, knowledge, and practices for use of HD-IIV and LAIV during the 2016-2017 and 2018-2019 influenza seasons.
Design: E-mail and mail surveys conducted February-March 2017, January-February 2019.
Participants: Nationally representative samples of FPs and GIMs.
Main measures: Surveys assessed HD-IIV practices (2017), knowledge and perceptions (2019), and LAIV knowledge and practices (2017, 2019).
Key results: Response rates were 67% (620/930) in 2017 and 69% (642/926) in 2019. Many physicians believed HD-IIV is more effective than standard dose IIV in patients ≥ 65 years (76%) and reported their patients ≥ 65 years believe they need HD-IIV (67%). Most respondents incorrectly thought ACIP preferentially recommends HD-IIV for adults ≥ 65 years (88%); 65% "almost always/always" recommended HD-IIV for adults ≥ 65 years. Some physicians incorrectly thought ACIP preferentially recommends HD-IIV for adults < 65 years with cardiopulmonary disease (38%) or immunosuppression (48%); some respondents recommended HD-IIV for these groups (25% and 28% respectively). In 2017, 88% of respondents knew that ACIP recommended against using LAIV during the 2016-2017 influenza season, and 4% recommended LAIV to patients. In 2019, 63% knew that ACIP recommended that LAIV could be used during the 2018-2019 influenza season, and 8% recommended LAIV.
Conclusions: Many physicians incorrectly thought ACIP had preferential recommendations for HD-IIV. Physicians should be encouraged to use any available age-appropriate influenza vaccine to optimize influenza vaccination particularly among older adults and patients with chronic conditions who are more vulnerable to severe influenza disease.
Keywords: immunization; influenza; influenza vaccine; vaccination.